Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Intestinal Fistula Treatment Market Snapshot (2023 to 2033)

The global intestinal fistula treatment market is expected to be valued at US$ 26.64 Billion in 2023. With the continuous improvements in drugs and biotechnology, the overall demand for Intestinal Fistula Treatment is projected to grow at a CAGR of 5.8% between 2023 and 2033, totaling around US$ 46.82 Billion by 2033.

Data Points Key Statistics
Expected Market Value for Intestinal Fistula Treatment in 2023 US$ 26.64 Billion
Projected Market Value for Intestinal Fistula Treatment in 2033 US$ 46.82 Billion
Global Growth Rate (2023 to 2033) CAGR of 5.8%

According to the analysis of Future Market Insights, factors such as a rise in the inflammatory bowel disease (IBD) patient pool, increase in the prevalence of Crohn’s disease, approval of new biologic drugs, novel drugs pipeline, and increase in demand for application of intestinal fistula treatment in developing countries are expected to augment the growth of the intestinal fistula treatment market.

Reimbursement plans introduced by the leading players to cushion healthcare expenditure will lead to positive sentiment among patients toward effective treatment. Growth in investments in the treatment of intestinal fistula is also anticipated to help achieve high ROI, as physicians tend to prescribe these drugs for the treatment of moderate to severe intestinal fistula. In addition, the development of anti-adhesion molecules is likely to propel the adoption of integrin antagonists.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Intestinal Fistula Treatment Demand Analysis (2018 to 2022) Vs Market Outlook (2023 to 2033)

The global demand for intestinal fistula treatment is projected to increase at a CAGR of 5.8% during the forecast period between 2023 and 2033, reaching a total of US$ 46.82 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 3.2%. According to Future Market Insights, a market research and competitive intelligence provider, the Intestinal Fistula Treatment market was valued at US$ 25.18 Billion in 2022.

The global rise in the prevalence of intestinal fistula is driving the growth of the intestinal fistula treatment market. The major cause of the disease includes inflammatory bowel diseases, which result in long-term chronic inflammation of the gastrointestinal (GI) tract without any known cause. Factors such as innovations in product development, approval of drugs, and rising inclination toward the use of biologic and biosimilar drugs are expected to boost the revenue share of intestinal fistula treatment during the forecast period. Growth in sales of intestinal fistula drugs through online, retail, and hospital pharmacies is helping companies generate more revenues. For instance, in December 2019, the FDA approved two biosimilars - adalimumab and infliximab - for the treatment of Ulcerative Colitis.

Biopharmaceutical companies have made significant investments in Research and Development activities. Large numbers of pipeline products are in different stages of clinical approvals, which are likely to commercialize over the analysis period. According to a report, around 2.5 million people in the USA suffered from inflammatory bowel disease in 2020. The prevalence of IBD among the USA population is expected to rise to around 3.5 million by 2030. Similarly, data suggest that the incidence and prevalence of inflammatory bowel diseases [IBD] are still increasing in Europe; around 0.2% of the population of Europe suffered from IBD in 2020. This in turn is anticipated to accelerate market growth in the forthcoming years.

Which Drivers underpin Intestinal Fistula Treatment Industry Expansion?

Increasing focus on Research and Development for the Treatment of Intestinal Fistula to Fuel the Market Growth

Technological development, such as the use of single-cell RNA sequencing, is helping healthcare professionals in the treatment of intestinal fistula treatment. High-dimensional technologies such as single-cell RNA sequencing and mass cytometry have been performed on the intestinal specimens collected from patients suffering from Crohn’s disease or ulcerative colitis. Several benefits of the single-cell RNA sequencing analysis used to understand the molecular basis of the disease include the development of novel therapeutic approaches, optimizing the individual medicines, and preventing the disease.

For instance, in August 2020, The University of California and VA San Diego Healthcare System (VASDHS) used transcriptomic and antigen receptor sequencing strategies to characterize tissue and immune cell features in individuals with or without ulcerative colitis. These advancements in technology provide an unusual view of immune cell networks in health and disease. These factors are expected to escalate the growth of the intestinal fistula treatment market during the forecast period.

Rise in Awareness Regarding Intestinal Fistula to Accelerate the Market Growth

There are numerous factors that are responsible for the increasing prevalence of intestinal fistula treatment market, which are genetic predisposition, environmental triggers, and immune system disturbance, which all are results of Crohn’s Disease. The majority of the patients suffering from ulcerative colitis or Crohn’s disease have a family history of the disorder.

For instance, according to a research study conducted by Hopkins Medicine, about 10 to 15% of the patients suffering from Crohn’s disease have a family history of the disorder. Approximately 5 to 7% of the patients suffering from ulcerative colitis have a family history of the disorder.

Various government organizations are creating awareness about intestinal fistula by educating people about the symptoms, diagnosis, and treatments available for the condition. Hence, the rising awareness about the treatment options available and the increasing rate of disease diagnosis in developing countries are projected to support the market growth. Thus, the aforementioned factors are leading to increasing demand for drugs over the analysis period.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Which Factors are limiting the Growth of Intestinal Fistula Treatment Market?

High Cost of Intestinal Fistula Drugs to Limit the Market Growth

The high treatment cost of the intestinal fistula, including the drug cost and other costs, reducing the number of patients undergoing treatment are expected to hinder the adoption of intestinal fistula treatment in patients. Additionally, the adoption of biologics is increasing to treat the disease, but the high costs associated with biologics treatment are limiting the market growth.

For instance, according to the National Center for Biotechnology Information (NCBI), the average annual cost of Adalimumab per person is about USD 12,343 in the United Kingdom In emerging countries, such as India, China, and Russia, there is a lack of reimbursement for intestinal fistula treatment, limiting the adoption of these drugs in the region. Hence, the high cost of medications for treating the disease and the lack of reimbursement policies in developing countries are anticipated to impede market growth in the near future.

Region-wise Insights

Will North America Continue Dominance in the Global Intestinal Fistula Treatment Market?

Increase in Prevalence of Ulcerative Colitis in the Region to Fuel the Market Growth

The intestinal fistula treatment market in North America is expected to accumulate the highest market share of 45% in 2023. Factors such as the high prevalence and increase in the incidence of ulcerative colitis and Crohn’s disease in the USA and Canada, well-established healthcare infrastructure, and high risk of lifestyle-related factors are expected to augment the regional market growth during the forecast period.

Moreover, the strong product pipeline of key players is another major factor that is anticipated to fuel the market growth in the region. For instance, according to the National Center for Biotechnology Information (NCBI), the prevalence of inflammatory bowel disease in Canada will be over 0.75% in 2021. The region is expected to hold the highest CAGR of 5.7% during the forecast period.

How Will the Growth of the Intestinal Fistula Treatment Market unfold in the Asia Pacific?

Rising Awareness Regarding Available Treatment Options in the Region to Fuel the Market Growth

The intestinal fistula treatment market in the Asia Pacific is expected to accumulate the highest market share of 44% in 2023. The intestinal treatment market in China is anticipated to grow at a significant share over the analysis period. attributed to the factors such as an increase in the intestinal fistula patient pool and a rise in the focus of manufacturers on the development of novel therapeutics.

Additionally, factors including increasing awareness about available treatment options for the disease in the region and increasing approvals for the drugs for the treatment of the disease are also expected to fuel the regional market growth. For instance, in December 2021, Eisai Co., Ltd. and Gilead Sciences, Inc. agreed to the commercialization and distribution of filgotinib, an oral, JAK1 preferential inhibitor for indications of ulcerative colitis and Crohn's disease in Asia (South Korea, Taiwan, Hong Kong, and Singapore).

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Insights

By Drug Class, which Intestinal Fistula Treatment Category will remain prominent?

Proton-Pump Inhibitors Segment to beat Competition in Untiring Market

On the basis of drug class, proton-pump inhibitors are likely to account for 45% of all drug sales. The segment is expected to augment at a CAGR of 5.7% over the analysis period. Growth is attributed to the factors such as the fact that the PPIs inhibit acid secretion, whether promoted by histamine, acetylcholine, or gastrin.

Moreover, PPIs work by irreversibly blocking the H+/K+ ATPase enzyme or the gastric proton pump, which is found within the parietal cells of the stomach and is the final step of acid production. All these factors are expected to stimulate the segment’s growth during the forecast period.

By Distribution Channel, which Intestinal Fistula Treatment Category dominates?

Hospital Pharmacies account for the bulk of all Intestinal Fistula Treatment Medication Sales

Based on distribution channels, hospital pharmacies are expected to account for 46% of intestinal fistula treatment medication sales in 2023 and are expected to grow at a 5.6% CAGR until 2033. Growth is attributed to the fact that most of the major intestinal fistula treatment drugs and products are prescription products, which are available in hospital pharmacies.

Furthermore, the segment dominated the market with a significant share, attributed to reimbursement policies in developing countries, which cover the high cost of these drugs. For instance, according to Baylor Scott & White, in the USA, approximately 45% of the costs are covered by the pharmacy, including injectable drugs and others.

The Start-up Ecosystem: How key Players are opening Frontiers for Future Growth?

Intestinal Fistula Treatment Market startup players are adopting various marketing strategies such as new product launches, geographical expansion, mergers and acquisitions, partnerships, and collaboration to identify the interest of potential patients and create a larger customer base. For instance,

  • In June 2021, Gusto Global, a microbiome discovery platform company focused on restoring a healthy microbiome, developed novel consortia of bacteria for treating Crohn’s disease and ulcerative colitis in patients.
  • In April 2019, Signum Surgical, an Ireland-based startup landed more than $3 million in grants to help fund its efforts to gain U.S. and European regulatory clearance for a device intended to treat a condition that can cause fecal incontinence. The BioHealx technology is designed to treat anal fistula.
  • In May 2018, Oshi Health, a digital startup focused on digestive health, launched a mobile app specifically designed to help inflammatory bowel disease patients understand and manage their condition. The app has an all-in-one mobile platform with three primary aims: condition and lifestyle tracking, patient education, and active IBD management.

Who are the Leading Players in the Intestinal Fistula Treatment Market?

Prominent players in the intestinal fistula treatment market are:

  • Livealth BioPharma
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc.
  • Apsolabs
  • AstraZeneca
  • Pipelinepharma
  • Astellas Pharma Inc.
  • Caspian Tamin Pharmaceutical Company
  • Eli Lilly
  • GlaxoSmithKline
  • Bristol-Myers Squibb
  • Merck & Co. KGaA
  • Moderna Inc.

Recent Developments:

  • In December 2022, Moderna, Inc., and Merck announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA®, Merck’s anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of recurrence-free survival (RFS) versus KEYTRUDA alone for the adjuvant treatment of patients with stage III/IV melanoma following complete resection. Adjuvant treatment with mRNA-4157/V940 in combination with KEYTRUDA reduced the risk of recurrence or death by 44% (HR=0.56 [95% CI, 0.31-1.08]; one-sided p value=0.0266) compared with KEYTRUDA alone.
  • In September 2022, Bristol Myers Squibb announced that the Phase 3 CheckMate -76K trial evaluating Opdivo (nivolumab) as a single agent in the adjuvant setting in patients with completely resected stage IIB/C melanoma met its primary endpoint and demonstrated a statistically significant and clinically meaningful benefit in recurrence-free survival (RFS) versus placebo at a pre-specified interim analysis. No new safety signals were observed at the time of the analysis.

Report Scope

Report Attribute Details
Growth Rate CAGR of 5.8% from 2023 to 2033
Market Value in 2023 US$ 26.64 Billion
Market Value in 2033 US$ 46.82 Billion
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ Billion and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Drug Class
  • Route of Administration
  • Distribution Channel
  • Region
Regions Covered
  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • Middle East & Africa
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Mexico
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • China
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Singapore
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • Livealth BioPharma
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc.
  • Apsolabs
  • AstraZeneca
  • Pipelinepharma
  • Astellas Pharma Inc.
  • Caspian Tamin Pharmaceutical Company
  • Eli Lilly
  • GlaxoSmithKline
  • Bristol-Myers Squibb
  • Merck & Co. KGaA
  • Moderna Inc.
Customization Available upon Request

Key Segments Covered in the Intestinal Fistula Treatment Industry Analysis

By Drug Class:

  • Anticholinergic
  • Proton-Pump Inhibitors
  • H2 Blockers
  • Antidiarrheals

By Route of Administration:

  • Oral
  • Parenteral
  • Rectal
  • Transdermal
  • Intravenous

By Distribution Channel:

  • Hospital Pharmacies
  • Clinical Pharmacies
  • Drug Stores
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Frequently Asked Questions

What is Asia Pacific's Share in the Intestinal Fistula Treatment Market?

Asia Pacific is expected to accumulate a market share of 44% in 2023.

What is the Historical Outlook of the Market?

From 2018 to 2022, the market registered a CAGR of 5.8%.

What is the Growth Forecast for the Intestinal Fistula Treatment Market?

The market is likely to register a 5.8% CAGR Until 2033.

What is the Estimated Market Size by 2033?

The industry is expected to reach US$ 46.82 billion in 2033.

What is North America's Market Share?

North America is expected to accumulate a high market share of 45% in 2023.

Table of Content

1. Executive Summary | Intestinal Fistula Treatment Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Billion) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Billion) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Billion) Analysis By Drug Class, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By Drug Class, 2023 to 2033

        5.3.1. Anticholinergic

        5.3.2. Proton-pump Inhibitors

        5.3.3. H2 Blockers

        5.3.4. Antidiarrheals

    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Billion) Analysis By Route of Administration, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By Route of Administration, 2023 to 2033

        6.3.1. Oral

        6.3.2. Parenteral

        6.3.3. Rectal

        6.3.4. Transdermal

        6.3.5. Intravenous

    6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Billion) Analysis By Distribution Channel, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By Distribution Channel, 2023 to 2033

        7.3.1. Hospital Pharmacies

        7.3.2. Clinical Pharmacies

        7.3.3. Drug Stores

        7.3.4. Online Pharmacies

    7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Billion) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Billion) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. Asia Pacific

        8.3.5. Middle East and Africa(MEA)

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Drug Class

        9.2.3. By Route of Administration

        9.2.4. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Class

        9.3.3. By Route of Administration

        9.3.4. By Distribution Channel

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Drug Class

        10.2.3. By Route of Administration

        10.2.4. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

        10.3.3. By Route of Administration

        10.3.4. By Distribution Channel

    10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. United Kingdom

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Drug Class

        11.2.3. By Route of Administration

        11.2.4. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

        11.3.3. By Route of Administration

        11.3.4. By Distribution Channel

    11.4. Key Takeaways

12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

            12.2.1.4. Singapore

            12.2.1.5. Thailand

            12.2.1.6. Indonesia

            12.2.1.7. Australia

            12.2.1.8. New Zealand

            12.2.1.9. Rest of Asia Pacific

        12.2.2. By Drug Class

        12.2.3. By Route of Administration

        12.2.4. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class

        12.3.3. By Route of Administration

        12.3.4. By Distribution Channel

    12.4. Key Takeaways

13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. GCC Countries

            13.2.1.2. South Africa

            13.2.1.3. Israel

            13.2.1.4. Rest of Middle East and Africa(MEA)

        13.2.2. By Drug Class

        13.2.3. By Route of Administration

        13.2.4. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Class

        13.3.3. By Route of Administration

        13.3.4. By Distribution Channel

    13.4. Key Takeaways

14. Key Countries Market Analysis

    14.1. USA

        14.1.1. Pricing Analysis

        14.1.2. Market Share Analysis, 2022

            14.1.2.1. By Drug Class

            14.1.2.2. By Route of Administration

            14.1.2.3. By Distribution Channel

    14.2. Canada

        14.2.1. Pricing Analysis

        14.2.2. Market Share Analysis, 2022

            14.2.2.1. By Drug Class

            14.2.2.2. By Route of Administration

            14.2.2.3. By Distribution Channel

    14.3. Brazil

        14.3.1. Pricing Analysis

        14.3.2. Market Share Analysis, 2022

            14.3.2.1. By Drug Class

            14.3.2.2. By Route of Administration

            14.3.2.3. By Distribution Channel

    14.4. Mexico

        14.4.1. Pricing Analysis

        14.4.2. Market Share Analysis, 2022

            14.4.2.1. By Drug Class

            14.4.2.2. By Route of Administration

            14.4.2.3. By Distribution Channel

    14.5. Germany

        14.5.1. Pricing Analysis

        14.5.2. Market Share Analysis, 2022

            14.5.2.1. By Drug Class

            14.5.2.2. By Route of Administration

            14.5.2.3. By Distribution Channel

    14.6. United Kingdom

        14.6.1. Pricing Analysis

        14.6.2. Market Share Analysis, 2022

            14.6.2.1. By Drug Class

            14.6.2.2. By Route of Administration

            14.6.2.3. By Distribution Channel

    14.7. France

        14.7.1. Pricing Analysis

        14.7.2. Market Share Analysis, 2022

            14.7.2.1. By Drug Class

            14.7.2.2. By Route of Administration

            14.7.2.3. By Distribution Channel

    14.8. Spain

        14.8.1. Pricing Analysis

        14.8.2. Market Share Analysis, 2022

            14.8.2.1. By Drug Class

            14.8.2.2. By Route of Administration

            14.8.2.3. By Distribution Channel

    14.9. Italy

        14.9.1. Pricing Analysis

        14.9.2. Market Share Analysis, 2022

            14.9.2.1. By Drug Class

            14.9.2.2. By Route of Administration

            14.9.2.3. By Distribution Channel

    14.10. China

        14.10.1. Pricing Analysis

        14.10.2. Market Share Analysis, 2022

            14.10.2.1. By Drug Class

            14.10.2.2. By Route of Administration

            14.10.2.3. By Distribution Channel

    14.11. Japan

        14.11.1. Pricing Analysis

        14.11.2. Market Share Analysis, 2022

            14.11.2.1. By Drug Class

            14.11.2.2. By Route of Administration

            14.11.2.3. By Distribution Channel

    14.12. South Korea

        14.12.1. Pricing Analysis

        14.12.2. Market Share Analysis, 2022

            14.12.2.1. By Drug Class

            14.12.2.2. By Route of Administration

            14.12.2.3. By Distribution Channel

    14.13. Singapore

        14.13.1. Pricing Analysis

        14.13.2. Market Share Analysis, 2022

            14.13.2.1. By Drug Class

            14.13.2.2. By Route of Administration

            14.13.2.3. By Distribution Channel

    14.14. Thailand

        14.14.1. Pricing Analysis

        14.14.2. Market Share Analysis, 2022

            14.14.2.1. By Drug Class

            14.14.2.2. By Route of Administration

            14.14.2.3. By Distribution Channel

    14.15. Indonesia

        14.15.1. Pricing Analysis

        14.15.2. Market Share Analysis, 2022

            14.15.2.1. By Drug Class

            14.15.2.2. By Route of Administration

            14.15.2.3. By Distribution Channel

    14.16. Australia

        14.16.1. Pricing Analysis

        14.16.2. Market Share Analysis, 2022

            14.16.2.1. By Drug Class

            14.16.2.2. By Route of Administration

            14.16.2.3. By Distribution Channel

    14.17. New Zealand

        14.17.1. Pricing Analysis

        14.17.2. Market Share Analysis, 2022

            14.17.2.1. By Drug Class

            14.17.2.2. By Route of Administration

            14.17.2.3. By Distribution Channel

    14.18. GCC Countries

        14.18.1. Pricing Analysis

        14.18.2. Market Share Analysis, 2022

            14.18.2.1. By Drug Class

            14.18.2.2. By Route of Administration

            14.18.2.3. By Distribution Channel

    14.19. South Africa

        14.19.1. Pricing Analysis

        14.19.2. Market Share Analysis, 2022

            14.19.2.1. By Drug Class

            14.19.2.2. By Route of Administration

            14.19.2.3. By Distribution Channel

    14.20. Israel

        14.20.1. Pricing Analysis

        14.20.2. Market Share Analysis, 2022

            14.20.2.1. By Drug Class

            14.20.2.2. By Route of Administration

            14.20.2.3. By Distribution Channel

15. Market Structure Analysis

    15.1. Competition Dashboard

    15.2. Competition Benchmarking

    15.3. Market Share Analysis of Top Players

        15.3.1. By Regional

        15.3.2. By Drug Class

        15.3.3. By Route of Administration

        15.3.4. By Distribution Channel

16. Competition Analysis

    16.1. Competition Deep Dive

        16.1.1. Livealth BioPharma

            16.1.1.1. Overview

            16.1.1.2. Product Portfolio

            16.1.1.3. Profitability by Market Segments

            16.1.1.4. Sales Footprint

            16.1.1.5. Strategy Overview

                16.1.1.5.1. Marketing Strategy

        16.1.2. Boehringer Ingelheim International GmbH

            16.1.2.1. Overview

            16.1.2.2. Product Portfolio

            16.1.2.3. Profitability by Market Segments

            16.1.2.4. Sales Footprint

            16.1.2.5. Strategy Overview

                16.1.2.5.1. Marketing Strategy

        16.1.3. Pfizer

            16.1.3.1. Overview

            16.1.3.2. Product Portfolio

            16.1.3.3. Profitability by Market Segments

            16.1.3.4. Sales Footprint

            16.1.3.5. Strategy Overview

                16.1.3.5.1. Marketing Strategy

        16.1.4. Apsolabs

            16.1.4.1. Overview

            16.1.4.2. Product Portfolio

            16.1.4.3. Profitability by Market Segments

            16.1.4.4. Sales Footprint

            16.1.4.5. Strategy Overview

                16.1.4.5.1. Marketing Strategy

        16.1.5. AstraZeneca

            16.1.5.1. Overview

            16.1.5.2. Product Portfolio

            16.1.5.3. Profitability by Market Segments

            16.1.5.4. Sales Footprint

            16.1.5.5. Strategy Overview

                16.1.5.5.1. Marketing Strategy

        16.1.6. Pipelinepharma

            16.1.6.1. Overview

            16.1.6.2. Product Portfolio

            16.1.6.3. Profitability by Market Segments

            16.1.6.4. Sales Footprint

            16.1.6.5. Strategy Overview

                16.1.6.5.1. Marketing Strategy

        16.1.7. Astellas Pharma Inc

            16.1.7.1. Overview

            16.1.7.2. Product Portfolio

            16.1.7.3. Profitability by Market Segments

            16.1.7.4. Sales Footprint

            16.1.7.5. Strategy Overview

                16.1.7.5.1. Marketing Strategy

        16.1.8. Caspian Tamin Pharmaceutical Company

            16.1.8.1. Overview

            16.1.8.2. Product Portfolio

            16.1.8.3. Profitability by Market Segments

            16.1.8.4. Sales Footprint

            16.1.8.5. Strategy Overview

                16.1.8.5.1. Marketing Strategy

        16.1.9. Eli Lilly

            16.1.9.1. Overview

            16.1.9.2. Product Portfolio

            16.1.9.3. Profitability by Market Segments

            16.1.9.4. Sales Footprint

            16.1.9.5. Strategy Overview

                16.1.9.5.1. Marketing Strategy

        16.1.10. GlaxoSmithKline

            16.1.10.1. Overview

            16.1.10.2. Product Portfolio

            16.1.10.3. Profitability by Market Segments

            16.1.10.4. Sales Footprint

            16.1.10.5. Strategy Overview

                16.1.10.5.1. Marketing Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 1: Global Market Value (US$ Billion) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Billion) Forecast by Drug Class, 2018 to 2033

Table 3: Global Market Value (US$ Billion) Forecast by Route of Administration, 2018 to 2033

Table 4: Global Market Value (US$ Billion) Forecast by Distribution Channel, 2018 to 2033

Table 5: North America Market Value (US$ Billion) Forecast by Country, 2018 to 2033

Table 6: North America Market Value (US$ Billion) Forecast by Drug Class, 2018 to 2033

Table 7: North America Market Value (US$ Billion) Forecast by Route of Administration, 2018 to 2033

Table 8: North America Market Value (US$ Billion) Forecast by Distribution Channel, 2018 to 2033

Table 9: Latin America Market Value (US$ Billion) Forecast by Country, 2018 to 2033

Table 10: Latin America Market Value (US$ Billion) Forecast by Drug Class, 2018 to 2033

Table 11: Latin America Market Value (US$ Billion) Forecast by Route of Administration, 2018 to 2033

Table 12: Latin America Market Value (US$ Billion) Forecast by Distribution Channel, 2018 to 2033

Table 13: Europe Market Value (US$ Billion) Forecast by Country, 2018 to 2033

Table 14: Europe Market Value (US$ Billion) Forecast by Drug Class, 2018 to 2033

Table 15: Europe Market Value (US$ Billion) Forecast by Route of Administration, 2018 to 2033

Table 16: Europe Market Value (US$ Billion) Forecast by Distribution Channel, 2018 to 2033

Table 17: Asia Pacific Market Value (US$ Billion) Forecast by Country, 2018 to 2033

Table 18: Asia Pacific Market Value (US$ Billion) Forecast by Drug Class, 2018 to 2033

Table 19: Asia Pacific Market Value (US$ Billion) Forecast by Route of Administration, 2018 to 2033

Table 20: Asia Pacific Market Value (US$ Billion) Forecast by Distribution Channel, 2018 to 2033

Table 21: MEA Market Value (US$ Billion) Forecast by Country, 2018 to 2033

Table 22: MEA Market Value (US$ Billion) Forecast by Drug Class, 2018 to 2033

Table 23: MEA Market Value (US$ Billion) Forecast by Route of Administration, 2018 to 2033

Table 24: MEA Market Value (US$ Billion) Forecast by Distribution Channel, 2018 to 2033
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 1: Global Market Value (US$ Billion) by Drug Class, 2023 to 2033

Figure 2: Global Market Value (US$ Billion) by Route of Administration, 2023 to 2033

Figure 3: Global Market Value (US$ Billion) by Distribution Channel, 2023 to 2033

Figure 4: Global Market Value (US$ Billion) by Region, 2023 to 2033

Figure 5: Global Market Value (US$ Billion) Analysis by Region, 2018 to 2033

Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 8: Global Market Value (US$ Billion) Analysis by Drug Class, 2018 to 2033

Figure 9: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 10: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 11: Global Market Value (US$ Billion) Analysis by Route of Administration, 2018 to 2033

Figure 12: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 13: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 14: Global Market Value (US$ Billion) Analysis by Distribution Channel, 2018 to 2033

Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 17: Global Market Attractiveness by Drug Class, 2023 to 2033

Figure 18: Global Market Attractiveness by Route of Administration, 2023 to 2033

Figure 19: Global Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 20: Global Market Attractiveness by Region, 2023 to 2033

Figure 21: North America Market Value (US$ Billion) by Drug Class, 2023 to 2033

Figure 22: North America Market Value (US$ Billion) by Route of Administration, 2023 to 2033

Figure 23: North America Market Value (US$ Billion) by Distribution Channel, 2023 to 2033

Figure 24: North America Market Value (US$ Billion) by Country, 2023 to 2033

Figure 25: North America Market Value (US$ Billion) Analysis by Country, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 28: North America Market Value (US$ Billion) Analysis by Drug Class, 2018 to 2033

Figure 29: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 30: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 31: North America Market Value (US$ Billion) Analysis by Route of Administration, 2018 to 2033

Figure 32: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 33: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 34: North America Market Value (US$ Billion) Analysis by Distribution Channel, 2018 to 2033

Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 37: North America Market Attractiveness by Drug Class, 2023 to 2033

Figure 38: North America Market Attractiveness by Route of Administration, 2023 to 2033

Figure 39: North America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 40: North America Market Attractiveness by Country, 2023 to 2033

Figure 41: Latin America Market Value (US$ Billion) by Drug Class, 2023 to 2033

Figure 42: Latin America Market Value (US$ Billion) by Route of Administration, 2023 to 2033

Figure 43: Latin America Market Value (US$ Billion) by Distribution Channel, 2023 to 2033

Figure 44: Latin America Market Value (US$ Billion) by Country, 2023 to 2033

Figure 45: Latin America Market Value (US$ Billion) Analysis by Country, 2018 to 2033

Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 48: Latin America Market Value (US$ Billion) Analysis by Drug Class, 2018 to 2033

Figure 49: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 51: Latin America Market Value (US$ Billion) Analysis by Route of Administration, 2018 to 2033

Figure 52: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 54: Latin America Market Value (US$ Billion) Analysis by Distribution Channel, 2018 to 2033

Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 57: Latin America Market Attractiveness by Drug Class, 2023 to 2033

Figure 58: Latin America Market Attractiveness by Route of Administration, 2023 to 2033

Figure 59: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 61: Europe Market Value (US$ Billion) by Drug Class, 2023 to 2033

Figure 62: Europe Market Value (US$ Billion) by Route of Administration, 2023 to 2033

Figure 63: Europe Market Value (US$ Billion) by Distribution Channel, 2023 to 2033

Figure 64: Europe Market Value (US$ Billion) by Country, 2023 to 2033

Figure 65: Europe Market Value (US$ Billion) Analysis by Country, 2018 to 2033

Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 68: Europe Market Value (US$ Billion) Analysis by Drug Class, 2018 to 2033

Figure 69: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 70: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 71: Europe Market Value (US$ Billion) Analysis by Route of Administration, 2018 to 2033

Figure 72: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 73: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 74: Europe Market Value (US$ Billion) Analysis by Distribution Channel, 2018 to 2033

Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 77: Europe Market Attractiveness by Drug Class, 2023 to 2033

Figure 78: Europe Market Attractiveness by Route of Administration, 2023 to 2033

Figure 79: Europe Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 80: Europe Market Attractiveness by Country, 2023 to 2033

Figure 81: Asia Pacific Market Value (US$ Billion) by Drug Class, 2023 to 2033

Figure 82: Asia Pacific Market Value (US$ Billion) by Route of Administration, 2023 to 2033

Figure 83: Asia Pacific Market Value (US$ Billion) by Distribution Channel, 2023 to 2033

Figure 84: Asia Pacific Market Value (US$ Billion) by Country, 2023 to 2033

Figure 85: Asia Pacific Market Value (US$ Billion) Analysis by Country, 2018 to 2033

Figure 86: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 87: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 88: Asia Pacific Market Value (US$ Billion) Analysis by Drug Class, 2018 to 2033

Figure 89: Asia Pacific Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 90: Asia Pacific Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 91: Asia Pacific Market Value (US$ Billion) Analysis by Route of Administration, 2018 to 2033

Figure 92: Asia Pacific Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 93: Asia Pacific Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 94: Asia Pacific Market Value (US$ Billion) Analysis by Distribution Channel, 2018 to 2033

Figure 95: Asia Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 96: Asia Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 97: Asia Pacific Market Attractiveness by Drug Class, 2023 to 2033

Figure 98: Asia Pacific Market Attractiveness by Route of Administration, 2023 to 2033

Figure 99: Asia Pacific Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 100: Asia Pacific Market Attractiveness by Country, 2023 to 2033

Figure 101: MEA Market Value (US$ Billion) by Drug Class, 2023 to 2033

Figure 102: MEA Market Value (US$ Billion) by Route of Administration, 2023 to 2033

Figure 103: MEA Market Value (US$ Billion) by Distribution Channel, 2023 to 2033

Figure 104: MEA Market Value (US$ Billion) by Country, 2023 to 2033

Figure 105: MEA Market Value (US$ Billion) Analysis by Country, 2018 to 2033

Figure 106: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 107: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 108: MEA Market Value (US$ Billion) Analysis by Drug Class, 2018 to 2033

Figure 109: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 110: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 111: MEA Market Value (US$ Billion) Analysis by Route of Administration, 2018 to 2033

Figure 112: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 113: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 114: MEA Market Value (US$ Billion) Analysis by Distribution Channel, 2018 to 2033

Figure 115: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 116: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 117: MEA Market Attractiveness by Drug Class, 2023 to 2033

Figure 118: MEA Market Attractiveness by Route of Administration, 2023 to 2033

Figure 119: MEA Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 120: MEA Market Attractiveness by Country, 2023 to 2033

Recommendations

Healthcare

Rare Gastrointestinal Diseases Treatment Market

Published : August 2023

Healthcare

Arteriovenous Fistula Treatment Market

Published : July 2023

Healthcare

Intestinal Pseudo-Obstruction Treatment Market

Published : February 2023

Healthcare

Gastrointestinal Stent Market

Published : February 2023

Explore Healthcare Insights

View Reports

Intestinal Fistula Treatment Market